Sfoglia per Autore
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials
2022 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Massari F.
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
2022 Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fiorentino M.; Massari F.
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D.
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
2022 Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.; Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F.
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
2023 Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, Costantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco
Prostate cancer and novel pharmacological treatment options - what's new for 2022?
2023 Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab
2023 Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
2023 Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rosellini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis
2023 Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
2023 Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer
2023 Nuvola, Giacomo; Santoni, Matteo; Rizzo, Mimma; Rosellini, Matteo; Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Battelli, Nicola; Massari, Francesco
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
2023 Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
2024 Maffezzoli, Michele; Santoni, Matteo; Mazzaschi, Giulia; Rodella, Sara; Lai, Eleonora; Maruzzo, Marco; Basso, Umberto; Bimbatti, Davide; Iacovelli, Roberto; Anghelone, Annunziato; Fiala, Ondřej; Rebuzzi, Sara Elena; Fornarini, Giuseppe; Lolli, Cristian; Massari, Francesco; Rosellini, Matteo; Mollica, Veronica; Nasso, Cecilia; Acunzo, Alessandro; Silini, Enrico Maria; Quaini, Federico; De Filippo, Massimo; Brunelli, Matteo; Banna, Giuseppe L; Rescigno, Pasquale; Signori, Alessio; Buti, Sebastiano
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?
2024 Tassinari, Elisa; Rosellini, Matteo; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials | Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Massari F. | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers | Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fio...rentino M.; Massari F. | 2022-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti... G.; Campana D. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Vescica_SEER.pdf; curroncol-29-00461-s001.zip |
| Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma | Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.;... Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F. | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer | Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? | Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, C...ostantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco | 2023-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | Molecular Diagn Ther 2023 [Neoadj UC].pdf |
| Prostate cancer and novel pharmacological treatment options - what's new for 2022? | Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mo...llica, Veronica | 2023-01-01 | EXPERT REVIEW OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab | Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca...; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco | 2023-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study | Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rose...llini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CLINICAL AND EXPERIMENTAL MEDICINE | - | 1.01 Articolo in rivista | Clin Exp Med. 2023 [MOUSEION 06].pdf |
| Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis | Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronic...a; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo,... Alessandro; Massari, Francesco; Mollica, Veronica | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study | Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rose...llini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer | Nuvola, Giacomo; Santoni, Matteo; Rizzo, Mimma; Rosellini, Matteo; Mollica, Veronica; Rizzo, Ales...sandro; Marchetti, Andrea; Battelli, Nicola; Massari, Francesco | 2023-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis | Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchet...ti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco | 2023-01-01 | EUROPEAN UROLOGY | - | 1.01 Articolo in rivista | - |
| External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations | Maffezzoli, Michele; Santoni, Matteo; Mazzaschi, Giulia; Rodella, Sara; Lai, Eleonora; Maruzzo, M...arco; Basso, Umberto; Bimbatti, Davide; Iacovelli, Roberto; Anghelone, Annunziato; Fiala, Ondřej; Rebuzzi, Sara Elena; Fornarini, Giuseppe; Lolli, Cristian; Massari, Francesco; Rosellini, Matteo; Mollica, Veronica; Nasso, Cecilia; Acunzo, Alessandro; Silini, Enrico Maria; Quaini, Federico; De Filippo, Massimo; Brunelli, Matteo; Banna, Giuseppe L; Rescigno, Pasquale; Signori, Alessio; Buti, Sebastiano | 2024-01-01 | CLINICAL & EXPERIMENTAL METASTASIS | - | 1.01 Articolo in rivista | Clin Exp Metastasis 2024 [Red cell Buti].pdf; 10585_2024_10266_MOESM1_ESM.docx |
| What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? | Tassinari, Elisa; Rosellini, Matteo; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco | 2024-01-01 | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile